A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

NCT07283705•M.D. Anderson Cancer Center

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Phase 2 StudyBMS-986504MTAP-deleted Pancreatic Cancer

Interventions

BMS-986504

Gemcitabine

+2 more

Locations

United States

Locations (1)

MD Anderson Cancer Center

Houston, Texas, United States

Key Dates

Start Date

May 18, 2026

Primary Completion Date

October 1, 2029

Completion Date

October 1, 2031

Last Updated

April 16, 2026

Contacts

Maria P Morelli, MD

CONTACT

713-745-1297 giclinicaltrials@mdanderson.org

Sponsors

Lead Sponsor

M.D. Anderson Cancer Center

Collaborators

Bristol-Myers Squibb

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 16, 2026Data synced to Clareo: April 27, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions